Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm
Conditions
Interventions
FlecIH-103
Locations
40
United States
UC Davis Medical Center
Davis, California, United States
Memorial Care
Long Beach, California, United States
Bridgeport Hospital
Bridgeport, Connecticut, United States
Orlando Health Heart and Vascular Institute and Orlando Regional medical Center
Orlando, Florida, United States
Tampa General Hospital; Center of Research Excellence
Tampa, Florida, United States
IU Health Ball Memorial Hospital
Muncie, Indiana, United States
Start Date
April 26, 2022
Primary Completion Date
May 22, 2023
Completion Date
May 22, 2023
Last Updated
October 30, 2023
NCT07281898
NCT06765356
NCT06106594
NCT05172765
NCT06431815
NCT05462145
Lead Sponsor
InCarda Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions